Skip to main content
Fig. 3 | BMC Infectious Diseases

Fig. 3

From: COVID-19 monoclonal antibody treatment impact on symptoms and post-COVID conditions among high-risk patients at a Federally Qualified Health Center

Fig. 3

Symptom severity at D14 vs. D28+ surveys (N = 199). Among patients who completed the Baseline, D14, and D28+ Surveys. Follow-up times for the surveys varied. “None” defined as no mild, moderate, or severe symptoms; “Mild” defined as ≥ 1 mild symptom (and no moderate or severe symptoms); “Moderate” defined as ≥ 1 moderate symptom (and no severe symptoms); “Severe” defined as ≥ 1 severe symptom. The following symptoms were excluded from calculations because of how their severity levels were classified: vomiting, diarrhea, loss of hearing, anosmia, and ageusia

Back to article page